RNA Stock Summary and Trading Ideas (Avidity Biosciences | NASDAQ:RNA)

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Avidity Biosciences trades on the NASDAQ stock market under the symbol RNA.

As of February 4, 2026, RNA stock price declined to $72.72 with 3,476,858 million shares trading.

RNA has a beta of 1.14, meaning it tends to be more sensitive to market movements. RNA has a correlation of 0.10 to the broad based SPY ETF.

RNA has a market cap of $11.23 billion. This is considered a Large Cap stock.

Last quarter Avidity Biosciences reported $12 million in Revenue and -$1.27 earnings per share. This beat revenue expectation by $10 million and missed earnings estimates by -$.19.

In the last 3 years, RNA traded as high as $73.06 and as low as $4.83.

The top ETF exchange traded funds that RNA belongs to (by Net Assets): VTI, VB, IWM, VXF, XBI.

RNA has outperformed the market in the last year with a return of +127.5%, while the SPY ETF gained +16.0%. In the last 3 month period, RNA beat the market returning +4.2%, while SPY returned +0.7%. However, in the most recent 2 weeks RNA has underperformed the stock market by returning +0.3%, while SPY returned +1.3%.

RNA support price is $72.81 and resistance is $73.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNA shares will trade within this expected range on the day.